Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Company Deals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Fineline Cube Jul 9, 2026
Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Fineline Cube Jul 9, 2026
Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Fineline Cube Jul 9, 2026
Company Medical Device

Intuitive Surgical-Fosun Medical Launches Da Vinci Xi Surgical Robot at CIIE

Fineline Cube Nov 7, 2023

Intuitive Surgical-Fosun Medical Technology (Shanghai) Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group)...

Company Deals

BioNTech Secures Exclusive Rights to Biotheus Inc.’s BsAb PM8002 in Landmark Deal

Fineline Cube Nov 7, 2023

Germany’s BioNTech (NASDAQ: BNTX) has entered into an exclusive license and collaboration agreement with China-based...

Company Drug

MicuRx Pharmaceuticals Secures Clinical Trial Approvals for MRX-4 and Contezolid in Multiple Countries

Fineline Cube Nov 6, 2023

Sino-US firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has announced that it has received clinical trial...

Company Deals

Baheal Pharmaceutical Partners with AstraZeneca for Exclusive Distribution of Losec in China

Fineline Cube Nov 6, 2023

China-based health services and distribution giant Baheal Pharmaceutical Group has announced a strategic partnership with...

Company Deals

CORXEL Partners with WuXi STA for Sterile Nasal Spray Production

Fineline Cube Nov 6, 2023

Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, backed by RTW Investments, has formed a...

Company Drug

Bayer Unveils Real-World Insights on Kerendia for CKD and T2D Management

Fineline Cube Nov 6, 2023

Germany-headquartered Bayer (ETR: BAYN) recently published interim insights from a significant real-world observational study focusing...

Company Drug

Seagen’s Adcetris Combo with Keytruda Shows Promising Results in Phase II Study

Fineline Cube Nov 6, 2023

Seagen (NASDAQ: SGEN), currently in the process of being acquired by Pfizer (NYSE: PFE), has...

Company Drug

AstraZeneca Announces Positive Phase IIb Results for CKD Treatment Combination

Fineline Cube Nov 6, 2023

UK-based pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) announced last week that its combination therapy of...

Deals R&D

HKU and SIIDB Collaborate on Drug Development for Infectious Diseases

Fineline Cube Nov 6, 2023

The Department of Microbiology at the University of Hong Kong (HKU) and the Shanghai Institute...

Company Drug

Dizal Pharmaceutical Presents Updates on DZD8586 and Golidocitinib at ASH Annual Meeting

Fineline Cube Nov 6, 2023

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) provided updates on the clinical development of its...

Company Deals

XtalPi Inc. and CK Life Sciences Expand Partnership to Develop AI-Powered Cancer Diagnostics

Fineline Cube Nov 6, 2023

Sino-US artificial intelligence (AI) firm XtalPi (QuantumPharm, HKG: 2228) has announced a strategic partnership agreement...

Company Drug

Zhejiang Huahai Pharmaceutical’s HB0052 Receives US FDA IND Approval for Solid Tumors

Fineline Cube Nov 6, 2023

IntroductionZhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521), a China-based pharmaceutical company, has announced that it...

Company Drug

BeiGene’s ZW25 on Track for Priority Review for Cholangiocarcinoma Treatment by CDE

Fineline Cube Nov 6, 2023

The Center for Drug Evaluation (CDE) website has indicated that BeiGene’s (NASDAQ: BGNE) ZW25 (zanidatamab)...

Company Drug

Innovent Biologics Presents Positive Clinical Results for Efdamrofusp Alfa and IBI324 at AAO

Fineline Cube Nov 6, 2023

Innovent Biologics, Inc. (HKG: 1801), a China-based biopharmaceutical company, has published the latest clinical results...

Company Drug

CSPC Pharmaceutical Group Gets NMPA Approval for SYS6011 Biologic Drug Clinical Study

Fineline Cube Nov 6, 2023

CSPC Pharmaceutical Group Ltd (HKG: 1093), a China-based pharmaceutical company, has announced that it has...

Company Deals

Bayer Extends Collaboration with Broad Institute to 2028 for Oncology Drug Targets and Therapies

Fineline Cube Nov 3, 2023

Germany’s Bayer (NYSE: ETR) has announced the extension of its 2013 collaboration agreement with the...

Company Deals

AbbVie Secures Option Agreement with Aldeyra Therapeutics for RASP Modulator Reproxalap

Fineline Cube Nov 3, 2023

AbbVie (NYSE: ABBV) has entered into an option agreement with Aldeyra Therapeutics (NASDAQ: ALDX), a...

Company

Novo Nordisk Reports 33% YOY Growth in Q3 2023 with Diabetes and Obesity Care Driving Sales

Fineline Cube Nov 3, 2023

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has released its Q3 2023 earnings report, showcasing...

Company Drug

Cutia Therapeutics Achieves Primary Endpoint in Phase I Study of CU-40101 for Androgenic Alopecia

Fineline Cube Nov 3, 2023

Cutia Therapeutics (HKG: 2487), a company specializing in dermatological therapies, has announced that its Phase...

Company Deals Drug

Sanofi Regains Exclusive Rights to Rezurock in China, Terminating Agreement with BioNova and BK Pharmaceuticals

Fineline Cube Nov 3, 2023

BioNova Pharmaceuticals, a Shanghai-based oncology-focused biopharmaceutical company founded in 2018, and Sanofi (NASDAQ: SNY), a...

Posts pagination

1 … 475 476 477 … 693

Recent updates

  • Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
  • Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs
  • Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial
  • Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST
  • Changchun High & New Technology’s Subsidiary GenSci Secures NMPA IND Acceptance for GenSci148, First-in-Class VEGF Multi-Blocker for Retinal Vascular Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Company Drug

Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.